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Introduction: Most studies on intracoronary bone marrow mononuclear cell transplantation for acute myocardial
infarction involve treatment 3–7 days after primary percutaneous coronary intervention (PCI); however, the optimal
timing is unknown. The present study assessed the therapeutic effect at different times after ST-elevation myocardial
infarction.
Methods: The present trial was not blinded. A total of 104 patients with a first ST-elevation myocardial infarction
and a left ventricular ejection fraction below 50 %, who had PCI of the infarct-related artery, were randomly
assigned to receive intracoronary infusion of bone marrow mononuclear cells within 24 hours (group A, n = 27), 3
to 7 days after PCI (group B, n = 26), or 7 to 30 days after PCI (group C, n = 26), or to the control group (n = 25),
which received saline infusion performed immediately after emergency PCI. All patients in groups A, B and C
received an injection of 15 ml cell suspension containing approximately 4.9 × 108 bone marrow mononuclear cells
into the infarct-related artery after successful PCI.
Results: Compared to control and group C patients, group A and B patients had a significantly higher absolute
increase in left ventricular ejection fraction from baseline to 12 months (change: 3.4 ± 5.7 % in control, 7.9 ± 4.9 %
in group A, 6.9 ± 3.9 % in group B, 4.7 ± 3.7 % in group C), a greater decrease in left ventricular end-systolic volumes
(change: −6.4 ± 15.9 ml in control, −20.5 ± 13.3 ml in group A, −19.6 ± 11.1 ml in group B, −9.4 ± 16.3 ml in group C),
and significantly greater myocardial perfusion (change from baseline: −4.7 ± 5.7 % in control, −7.8 ± 4.5 % in group
A, −7.5 ± 2.9 % in group B, −5.0 ± 4.0 % in group C). Group A and B patients had similar beneficial effects on
cardiac function (p = 0.163) and left ventricular geometry (left ventricular end-distolic volume: p = 0.685; left
ventricular end-systolic volume: p = 0.622) assessed by echocardiography, whereas group C showed similar results
to those of the control group. Group B showed more expensive care (p < 0.001) and longer hospital stays during
the first month after emergency PCI (p < 0.001) than group A, with a similar improvement after repeat cardiac
catheterization following emergency PCI.
Conclusion: Cell therapy in acute myocardial infarction patients that is given within 24 hours is similar to 3–7 days
after the primary PCI.
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On the basis of experimental studies that bone marrow
mononuclear cell (BMC) transfer in the injured tissue
can promote regional myocardial perfusion and im-
proved cardiac function, several clinical trials have
shown that intracoronary BMC transplantation in acute
myocardial infarction (AMI) patients several days after
myocardial reperfusion is safe and may enhance the im-
provement of left ventricular ejection fraction (LVEF)
[1–6]. The timing of BMC administration, baseline
LVEF, dosage of BMC and other factors have been linked
to improvement in LVEF after BMC transplantation. In
our previous work, we gave BMCs within 24 hours after
emergency percutaneous coronary intervention (PCI)
and found that it was safe and effective [7]. In addition,
there is another report with a longer time from symptom
onset to BMC infusion (2–4 weeks) which also appeared
effective [4]. The timing of intracoronary stem cell admin-
istration may have a critical effect on cell engraftment and
may be responsible for the various biological and func-
tional responses to therapy [8, 9]. However, few studies
have directly addressed the optimal timing of cell injec-
tions. Therefore, in this prospective randomized study,
BMCs were given at different times (within 24 hours, 3 to
7 days, or 7 to 30 days after reperfusion) to investigate
whether the timing of therapy affects the therapeutic re-
sponse of AMI patients.
Methods
Study protocols
Our institutional ethics committee (medical ethics com-
mittee of Zhongshan Hospital, Fudan University) approved
the study, and all patients gave their written informed con-
sent. The study was performed according to the principles
of the Declaration of Helsinki.
Patients with AMI who were admitted to Zhongshan
Hospital, Fudan University, China, were included. The
inclusion criteria were: aged 18 to 75 years; a history of
first acute ST-elevation myocardial infarction (STEMI);
treatment with PCI 2 to 12 hours after symptom onset;
successful PCI with stent implantation in the culprit lesion
of the infarct-related artery (IRA); and an LVEF <50 % on
angiography immediately after emergency PCI or rescue
PCI. The exclusion criteria were: previous Q-wave myo-
cardial infarction, cardiogenic shock, and severe coexisting
conditions such as acute and chronic heart failure, malig-
nant arrhythmia, renal failure and severe bleeding that in-
terfered with the ability of the patient to comply with the
protocol. All patients received medication according to
current guidelines.
The trial was not blinded. The day of acute PCI was
defined as day 0. On day 0, when patients were admitted
to the emergency room, they were informed regarding
random intracoronary BMC infusion if LVEF was lessthan 50 % after primary PCI. The informed consent in-
cluded the background, the purpose, and the proced-
ure of this trial. The risks and potential benefits of
BMC collection, preparation and transplantation were
described in detail. A minimum follow-up period of 1
year was requested from all patients. The patients had
the right to withdraw from the study at any time. Pa-
tients who refused to sign the informed consent were
excluded.
The patients enrolled in this trial were assigned to the
following groups: group A, intracoronary infusion of
BMC within 24 hours after PCI; group B, intracoronary
infusion of BMC 3 to 7 days after PCI; group C, intra-
coronary infusion of BMC 7 to 30 days after PCI; or the
control group (CON), which was given saline infusion
immediately after emergency PCI (Fig. 1). After the pri-
mary PCI, patients with LVEF ≥50 % were excluded. Fi-
nally, there were 27 patients in group A, 26 patients in
group B, 26 patients in group C and 25 patients in the
CON group.
For patients assigned to receive BMC, a bone marrow
sample (95 ± 16 ml) was collected at the designated time
points after primary PCI under local anesthesia from
both sides of the posterior superior iliac spine. To collect
sufficient amounts of bone marrow, several puncture
points were required. Patients received an injection of
15 ml cell suspension containing approximately 4.9 × 108
BMCs into the IRA within 3 hours after BMC collection.
Patients in group A remained in the cath-lab until the
entire procedure, including primary PCI and intracor-
onary BMC infusion, was completed. However, patients
in groups B and C, who underwent a second procedure,
to receive BMC transplantation in the cath-lab during
the same hospitalization or returned for a second
hospitalization. As shown in Fig. 1, after BMC trans-
plantation, all patients underwent clinical examinations,
onventional echocardiography, 201Ti single photon
emission computed tomography (SPECT), and coronary
angiography at the certain time-points. Major adverse
cardiac events and restenosis were recorded during the
12 months of follow-up.Cell preparation and administration
The BMCs were isolated by Ficoll density gradient cen-
trifugation and were infused into the IRA as described
previously [7]. Briefly, BMCs were isolated by Ficoll
density gradient centrifugation on Lymphocyte Separ-
ation Medium. Three washing steps were performed and
cells were resuspended in heparinized saline for use. Via-
bility was tested by Trypan Blue (exclusion method),
which showed a viability of more than 99 % cells for
each transplant. Repeated microbiological tests of the
cell suspensions performed prior to transplantation were
Fig. 1 (See legend on next page.)
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Fig. 1 Flow chart outlining the study protocol. A total of 104 acute myocardial infarction (AMI) patients were enrolled and randomly assigned to
four groups in this trial depending on bone marrow mononuclear cell (BMNC) transplantation after primary percutaneous coronary intervention
(PCI). Before discharge, the patients underwent echocardiography and single photon emission computed tomography (SPECT) and the data were
collected as baseline. At the 6-month follow-up, patients underwent angiography. The SPECT and echocardiography data were recorded at 6 and
12 months. Group A BMNC infusion within 24 hours after PCI; group B BMNC infusion at 3–7 days after PCI; group C BMNC infusion at 7–30 days
after PCI; LV, left ventricular; LVEF left ventricular ejection fraction
Huang et al. Stem Cell Research & Therapy  (2015) 6:112 Page 4 of 11negative for each transplant. The levels of CD34+ cells
and CD133+ cells were measured.
BMCs were infused into IRA at the site of the previous
occlusion. This was accomplished with the use of a mi-
crotubular. After positioning of the microtubular into
the distal segment vessel of the stent position in the
IRA, 15 mL of the whole cell suspension (groups A, B
and C) or saline (CON) was slowly administered via mi-
crotubular. The administration should be over 10 minutes
to prevent back-flow and to prolong cellular contact time
for cellular migration into the tissue. After completion of
intracoronary cell transplantation, coronary angiography
was repeated to ascertain vessel patency and unimpeded
flow of contrast material. During the process of intracoron-
ary infusion of BMCs, complications should be watched for,
including arrhythmia, bradycardia, sinus arrest or atrial
ventricular block, premature ventricular beats, ventricular
tachycardia, ventricular fibrillation, and hypotension, and
so forth.Hemodynamic assessment
LVEF, left ventricular end-diastolic volume (LVEDV),
and left ventricular end-systolic volume (LVESV) were
measured before discharge, at 6 months, and at 12 months
after intracoronary BMC infusion using two-dimensional
echocardiography according to Simpson’s method [10].
The measurements were repeated three times, and the
average was used for further calculations. All studies were
processed and evaluated in the echocardiogram laboratory
by experienced operators who were blinded to both the
order of the procedures and the assigned therapy.201Tl -SPECT imaging
As shown in Fig. 1, all patients underwent 1-day
electrocardio-gated stress Thallium-201 SPECT imaging
[11] before discharge, at 6 months, and 12 months after
intracoronary BMC infusion. All images were acquired
using a tri-head SPECT gamma camera (Philips-IRIX,
Philips Medical Systems, Milpitas, CA, USA). The myo-
cardial perfusion defect was automatically calculated
using ECTb3.0 software. Data were processed and evalu-
ated in the scintigraphic core laboratory by experienced
operators who were blinded to both the order of the pro-
cedures and the assigned therapy.Statistical analysis
Values for continuous variables that approximated a nor-
mal distribution are presented as means ± SD unless
otherwise noted. Univariate differences between groups
were performed with analysis of variance (ANOVA) for
multiple comparisons and Bonferroni’s post test. Statis-
tical comparisons between the initial and follow-up data
were performed with paired t test. Comparisons of the
changes from baseline to 12 months in the control and
BMC treatment groups were performed using repeated-
measures two-way ANOVA. The ANOVA model in-
cluded the control versus BMC treatments and baseline
versus 12 months as factors, and also included the inter-
action between the two factors. Categorical variables
were analyzed using the chi-square test or Fisher’s exact
test, as appropriate. A p value of less than 0.05 was consid-
ered to indicate statistical significance. All reported p values
are two-sided. Statistical analyses were performed using
STATA software (version 8.0, STATA, U.S.A.).
Results
Clinical characteristics
The baseline characteristics of the 104 patients are sum-
marized in Table 1. The average time from AMI to IRA
opening was 7 (2–12) hours. As shown in Table 1, the
four groups were comparable with respect to gender ra-
tio, age, family history of coronary heart diseases, history
of smoking, drinking, diabetes, hypertension, hyperlipid-
emia, hyperuricemia, interventional therapy, and other
variables. The average number of BMCs implanted was
(4.9 ± 2.8) × 108. The number of CD34+ cells and
CD133+ cells included in the implanted BMCs was
(1.4 ± 0.9) × 106 and (3.1 ± 2.2) × 105, respectively.
There was no difference in the number of BMC among
groups A, B, and C. Cell viability was tested using Trypan
Blue (exclusion method); more than 99 % of cells were vi-
able for each transplant.
Clinical outcomes during 12 months of follow-up
As shown in Fig. 1, of the 110 AMI patients, 104 were
enrolled; 84 had coronary arteriography at the 6-month
follow-up, and 85 completed 12 months of follow-up.
The peak creatinine kinase (CK)-MB and cardiac
troponin T (cTnT) levels and the time to peak for both
markers were not significantly different among the four
Table 1 Baseline clinical and angiographic characteristics
CON Group A Group B Group C p value
(n = 25) (n = 27) (n = 26) (n = 26)
Age, years 58.8 ± 8.4 60.0 ± 7.0 58.3 ± 9.8 57.3 ± 10.5 0.747
Female, % 12 7 12 8 0.915
Hypertension, % 48 59 50 73 0.490
Hyperlipidemia, % 48 26 65 42 0.281
Diabetes, % 32 31 15 15 0.544
Previous angina, % 24 30 23 31 0.901
Smoking (current or former), % 40 54 62 31 0.130
Family history for CAD, % 28 26 54 46 0.128
CAD (1-/2-/3-vessel disease), n 19/5/1 22/3/2 19/4/3 17/8/1 0.810
Infarct territory (anterior/inferior), % 85/15 70/30 69/27 73/23 0.564
Infarct-related vessel (LAD/RCA/LCX), % 80/16/4 82/11/7 73/23/4 73/19/8 0.911
Previous interventional therapy, n 3 5 2 4 0.638
PCI for additional stenosis in non-infarct-related vessels, n 3 4 3 4 0.970
Time to reperfusion/stent, hours 7.0 ± 2.1 7.0 ± 2.2 5.9 ± 3.5 6.6 ± 3.2 0.766
TIMI flow grade before PCI 0.32 ± 0.69 0.37 ± 0.69 0.31 ± 0.74 0.38 ± 0.80 0.977
Thrombolysis before PCI, n 5 4 3 7 0.702
Drug eluting stent/bare stent/no stent, n 10/15/0 19/8/0 10/14/2 10/14/2 0.766
GPIIb/IIIa inhibitor during acute PCI, % 20 15 12 15 0.876
Intravenous catecholamine, n 2 2 1 1 0.875
CPR during AMI, n 2 1 0 2 0.501
Creatine kinase MB max, U/L 158.6 ± 98.5 169.2 ± 102.0 153.8 ± 74.3 160.1 ± 88.1 0.940
Troponin T max, ng/mL 11.0 ± 10.3 10.0 ± 7.5 9.3 ± 9.0 8.9 ± 6.7 0.818
CRP max, mg/dl 12.3 ± 12.2 13.8 ± 12.4 12.3 ± 11.4 11.6 ± 7.5 0.901
White blood cells, ×109/L 9.3 ± 1.7 9.4 ± 2.7 9.4 ± 2.0 9.5 ± 2.3 0.990
Time from stent to cell therapy, hours – 1.6 ± 0.9 h 4.7 ± 1.3 d 11.1 ± 3.3d –
TIMI flow grade before study therapy 2.76 ± 0.44 2.89 ± 0.32 2.73 ± 0.45 2.81 ± 0.40 0.513
TIMI flow grade after study therapy 2.88 ± 0.33 2.93 ± 0.37 2.80 ± 0.40 2.88 ± 0.33 0.637
Number of BMC injected, ×108 – 4.8 ± 2.5 5.0 ± 3.8 4.8 ± 1.8 –
CD34+, ×106 – 1.8 ± 1.0 1.2 ± 0.8 0.9 ± 0.6 –
CD133+, ×105 – 4.1 ± 2.7 3.0 ± 2.0 2.3 ± 2.1 –
Baseline ejection fraction (echocardiography), % 43.5 ± 3.5 44.7 ± 3.9 43.1 ± 6.0 43.1 ± 6.4 0.603
End-diastolic volume, ml 157.7 ± 26.1 153.1 ± 27.9 151.7 ± 21.8 154.5 ± 26.7 0.639
End-systolic volume, ml 93.9 ± 17.3 90.8 ± 19.3 90.5 ± 18.3 97.0 ± 25.1 0.523
Medication at discharge
Aspirin (%) 100 96.1 100 100 0.420
Clopidogrel (%) 96.0 100 100 100 0.372
ACE inhibitor or ATII blocker, % 100 100 96.2 100 0.396
Beta-blocker, % 92.0 100 100 96.1 0.558
Statin, % 100 100 100 100 1.000
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Table 1 Baseline clinical and angiographic characteristics (Continued)
Medication at 12 months
Aspirin, % 96.0 96.2 100 100 0.573
Clopidogrel, % 88.0 77.8 80.8 88.5 0.435
ACE inhibitor or ATII blocker, % 96.0 92.6 92.0 96.1 0.894
Beta-blocker, % 96.0 92.3 100 96.1 0.589
Statin, % 96.0 92.3 96.1 96.1 0.914
ACE angiotensin converting enzyme; AMI acute myocardial infarction; ATII Angiotensin receptor inhibitor; CAD coronary artery disease; CON control group;
CPR cardiopulmonary resuscitation; CRP C-reactive protein; group A bone marrow mononuclear cell (BMC) infusion within 1 day after percutaneous coronary
intervention (PCI); group B BMC infusion at 3–7 days after PCI; group C BMC infusion at 7–30 days after PCI; LAD left anterior descending; LCX Left cyclotron;
PCI percutaneous coronary intervention; RCA right coronary artery; TIMI thrombolysis in myocardial infarction
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sensitive C-reactive protein (hsCRP) and CK-MB peak
values before or after the operation were detected among
the four groups. These results collectively suggest that no
inflammation or new myocardial lesions occurred after
cell transplantation.
No significant differences in the frequency of atrial
premature beats, ventricular extrasystole, atrial tachycar-
dia, and ventricular tachycardia on Holter monitoring were





MI relapse, n 0
Angina pectoris attack, n 3
Malignant arrhythmia, n 0
Fever (body temperature >37.5 °C) lasting at least 1 week 1
In-stent thrombus re-occlusion, n




MI relapse, n 2
Angina pectoris attack, n 2
Malignant arrhythmia, n 0
In-stent restenosis, n




Rehospitalization due to heart failure, n 4
Others, n 0
Combined events (death, recurrence of myocardial
infarction and rehospitalization for heart failure)
6
CON control group; group A bone marrow mononuclear cell (BMC) infusion within 1
3–7 days after PCI; group C BMC infusion at 7–30 days after PCI; MI myocardial infarNo proarrhythmic effects were detected on Holter mon-
itoring during follow-up. During follow-up, there were
no cases of death, tumor, or malignant arrhythmias.
Compared to the control group, the occurrence of the
combined clinical endpoint of death, MI recurrence,
and rehospitalization due to heart failure tended to be
lower in group A (p = 0.078) and group B (p = 0.214),
but not in group C (p = 0.673). There was no significant
difference in restenosis among the four groups (p > 0.05)
(as shown in Table 2).Group A Group B Group C p value
) (n = 27) (n = 26) (n = 26)
0 0 0 1.000
0 0 0 1.000
1 2 2 0.747
0 0 0 1.000
2 0 1 0.589
1 0 1 0.590
0 0 0 0.372
0 0 0 1.000
1 0 1 0.574
1 1 3 0.773
0 0 0 1.000
1 0 1 0.894
0 1 2 0.589
0 0 0 1.000
2 1 1 0.875
0 2 2 0.234
0 0 0 1.000
1 2 3 0.254
day after percutaneous coronary intervention (PCI); group B BMC infusion at
ct
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Baseline recordings were obtained for SPECT and echo-
cardiography at 2.1 ± 0.8 and 3.2 ± 0.6 days, respectively.
Baseline measurements of left ventricular function, vol-
umes, and myocardial perfusion did not differ signifi-
cantly among the four groups (Table 1). Compared with
baseline (Table 3), global LVEF in the four groups was
significantly increased on echocardiography at the 6-
month follow-up (44.7 ± 3.9 % to 50.4 ± 4.7 % in group
A, p < 0.001; 43.1 ± 6.0 % to 48.2 ± 6.4 % in group
B, p < 0.001; 43.1 ± 6.4 % to 46.8 ± 6.5 % in group
C, p < 0.001; 43.5 ± 3.5 % to 45.9 ± 5.4 % in CON,
p < 0.001), and it was further improved at 12 months
(52.2 ± 5.8 % in group A; 49.7 ± 5.6 % in group B; 47.4 ±
6.1 % in group C; 47.0 ± 6.9 % in CON). Compared to the
control group (Fig. 2), the absolute change in LVEF from
baseline to 12 months was significantly higher in groups
A and B (p = 0.007 for group A vs CON and p = 0.049 for
B vs CON), but not in group C (p = 0.919). Notably, the
improvement in LVEF was similar between groups A and
B (7.9 ± 4.9 % vs 6.9 ± 3.9 %, p = 0.455), and it was moreTable 3 Analysis of left ventricular ejection fraction and myocardial
emission computed tomography
CON (n = 25) Group
(95 % CI) (95 % C
Left ventricular ejection fraction on echocardiography, %
Baseline 43.5 ± 3.5 44.7 ±
(42.0 to 44.9) (43.2 to
6 months 45.9 ± 5.4* 50.4 ±
(43.5 to 48.3) (48.5 to
Change from baseline 2.4 ± 3.2 5.6 ± 3
(1.0 to 3.8) (4.3 to
12 months 47.0 ± 6.9* 52.2 ±
(43.9 to 50.1) (49.9 to
Change from baseline 3.4 ± 5.7 7.9 ± 4
(1.0 to 6.0) (6.0 to
Myocardial perfusion defect on (single photon emission computed tomograp
Baseline 42.0 ± 2.6 42.0 ±
(40.9 to 43.0) (40.5 to
6 months 38.2 ± 5.0* 36.4 ±
(35.9 to 40.5) (34.3 to
Change from baseline −3.5 ± 4.5 −5.7 ±
(−5.6 to −1.5) (−6.9 to
12 months 37.8 ± 6.0* 34.4 ±
(35.0 to 40.5) (31.7 to
Change from baseline −4.7 ± 5.7 −7.8 ±
(−7.2 to −2.1) (−9.6 to
*p < 0.05, vs baseline; †p < 0.05, vs control; ‡p < 0.05, vs group C. CON control grou
percutaneous coronary intervention (PCI); group B BMC infusion at 3–7 days after Psignificant in groups A and B than in group C (p < 0.01).
Moreover, the decrease in LVESV from baseline to 12
months did not differ between groups A and B (p = 0.656)
and between the CON group and group C (p = 0.468).
However, the LVESV decrease was greater in groups A
and B than in the CON group or group C (p < 0.05). By
contrast, there was no significant difference among the
four groups in the LVEDV decrease (p = 0.284) from base-
line to the 12-month follow-up (Table 4). In addition, the
201Ti-SPECT data obtained at 12 months showed that
myocardial perfusion was significantly enhanced in all four
groups (p < 0.05) (Table 3). However, there was no signifi-
cant difference in myocardial perfusion between groups A
and B (6 months: p = 0.482; 12 months: p = 0.761) and be-
tween the CON group and group C (6 months: p = 0.838;
12 months: p = 0.862). Taken together, these results sug-
gest that BMC transplantation within 24 hours or at 3–7
days after PCI further improves cardiac function in
addition to the benefits derived from PCI, whereas BMC
infusion performed later (7–30 days after acute PCI) offers
no additional benefit.perfusion defected by echocardiogram and 201Ti- single photon
A (n = 27) Group B (n = 26) Group C (n = 26)
I) (95 % CI) (95 % CI)
3.9 43.1 ± 6.0 43.1 ± 6.4
46.3) (40.7 to 45.5) (40.5 to 45.7)
4.7*†‡ 48.2 ± 6.4* 46.8 ± 6.5*
52.2) (45.2 to 51.2) (43.8 to 49.7)
.3†‡ 5.5 ± 2.2†‡ 2.9 ± 2.8
6.9) (4.4 to 6.5) (1.7 to 4.2)
5.8*†‡ 49.7 ± 5.6* 47.4 ± 6.1*
54.6) (46.9 to 52.5) (44.4 to 50.5)
.9†‡ 6.9 ± 3.9†‡ 4.7 ± 3.7
9.8) (5.0 to 8.8) (2.9 to 6.5)
hy), %
3.8 41.2 ± 7.1 42.4 ± 7.5
43.6) (38.3 to 44.2) (39.4 to 45.5)
5.2* 36.7 ± 6.7* 39.7 ± 7.0*
38.5) (33.5 to 39.8) (36.7 to 42.8)
3.1† −5.1 ± 3.0 −3.4 ± 3.2
−4.4) (−6.5 to −3.7) (−4.8 to −2.0)
6.5* 33.4 ± 6.6* 37.9 ± 7.0*
37.2) (30.0 to 36.8) (34.6 to 41.1)
4.5†‡ −7.5 ± 2.9†‡ −5.0 ± 4.0
−5.9) (−9.0 to −6.0) (−6.8 to −3.2)
p; group A bone marrow mononuclear cell (BMC) infusion within 1 day after
CI; group C BMC infusion at 7–30 days after PCI
Fig. 2 Left ventricular ejection fraction at baseline and at 12 months after myocardial infarction. Left ventricular ejection fraction (LVEF)
determined by echocardiography initially and at 12-month follow-up in the four groups. Compared with baseline, global LVEF in the four groups
was significantly increased on echocardiography at 12 months. Compared with the control group (CON), the absolute change in LVEF from baseline to
12 months was significantly higher in groups A and B, but not in group C. group A bone marrow mononuclear cell (BMC) infusion within 1 day after
percutaneous coronary intervention (PCI); group B BMC infusion at 3–7 days after PCI; group C BMC infusion at 7–30 days after PCI
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The principal finding of our study is that intracoronary
infusion of BMCs within 24 hours or at 3–7 days after
emergency PCI is associated with a significant increase
in the recovery of left ventricular contractile function
and remolding in AMI patients; intracoronary infusion
of BMC at 7–30 days after PCI had no significant effect.
Myocardial infarction leads to scar formation and a
subsequent reduction in cardiac performance. Stem cell-
based regeneration provides a new strategy for the treat-
ment of AMI patients. In addition to determining the
effects of stem cells on left ventricular function, the opti-
mal time window for cell infusion was also assessed.
Several recent trials have reported conflicting results
with respect to the optimal timing of cell therapy [2–6, 12].
The REPAIR-AMI trial found that the largest benefit oc-
curred when cells were injected 5 to 6 days after infarction
[5]. In another trial, patients with STEMI who underwent
intracoronary injection of autologous BMCs on day 7 or
after 6 months showed significant improvements in two-
dimensional systolic strain in all segments and in the in-
farcted area only in the BMC group [13]. Janssens et al. re-
ported no functional benefit derived from the injection of
cells within the first 24 hours after infarction [14]. On the
other hand, in our previous study with a small sample in
which we followed patients for 3 months, emergencyintracoronary administration of BMCs within 3 hours
after primary PCI was found to be safe and practical [5].
Intracoronary transfer of autologous BMCs in patients
with a healed myocardial infarct (13 ± 8 months) did not
lead to a significant improvement of cardiac systolic func-
tion, infarct size or myocardial perfusion [15].
The optimal time frame for intracoronary cell therapy
is a complex issue. It is probably determined by the
equilibrium between factors that facilitate and those that
inhibit the homing and cell survival that occurs during
the post-myocardial infarction inflammatory process [16,
17]. Given the biological time course of healing and the
expression of multiple factors, some researchers believe
that the highest probability for optimal nesting and sur-
vival is in the period between day 3 and day 7 [18]. On
the other hand, these factors are also related to stem cell
homing to the infarct zone, which suggests that cell infu-
sion in the early phase after myocardial infarction may
be equally effective [19].
The optimal time of cell delivery has not been deter-
mined to date. Our meta-analysis showed that BMC
transfer at 4 to 7 days post-AMI was the optimal time to
improve cardiac function in AMI patients [20]. There-
fore, in the present pilot study, we investigated the effect
of BMC infusions at different times from 24 hours to 1
month after myocardial infarction. Our present study
Table 4 LVEDV and LVESV derived from echocardiography analysis
CON (n = 25) Group A (n = 27) Group B (n = 26) Group C (n = 26)
(95 % CI) (95 % CI) (95 % CI) (95 % CI)
LVEDV by echocardiography, ml
Baseline 157.7 ± 26.1 153.1 ± 27.9 151.7 ± 21.8 154.5 ± 26.7
(148.0 to 167.3) (141.8 to 165.4) (142.9 to 160.5) (143.7 to 165.3)
6 months 156.9 ± 27.2 151.2 ± 26.3 149.8 ± 23. 5 152.8 ± 24.7
(144.8 to 168.9) (139.3 to 162.0) (138.6 to 158.1) (142.1 to 163.5)
Change from baseline −2.5 ± 14.5 −4.0 ± 11.3 −3.7 ± 12.5 −3.8 ± 15.4
(−8.9 to 3.9) (−10.5 to 1.8) (−9.3 to 2.7) (−10.4 to 2.9)
12 months 157.5 ± 27.6 149.4 ± 25.8† 148.5 ± 20.7† 150.2 ± 26.0
(145.3 to 169.7) (137.2 to 160.5) (137.9 to 156.2) (138.4 to 162.1)
Change from baseline −3.9 ± 18.7 −7.9 ± 13.9 −6.6 ± 10.6 −7.6 ± 18.0
(−12.2 to 4.4) (−14.3 to −0.8) (−11.5 to −1.4) (−15.8 to 0.6)
LVESV by echocardiography, ml
Baseline 93.9 ± 17.3 90.8 ± 19.3 90.5 ± 18.3 97.0 ± 25.1
(88.9 to 100.9) (83.0 to 98.6) (83.2 to 97.9) (86.8 to 107.1)
6 months 90.6 ± 21.4 77.2 ± 19.0*†‡ 83.2 ± 14.7 92.2 ± 21.6
(80.8 to 100.3) (69.3 to 85.0) (76.3 to 90.0) (82.9 to 101.6)
Change from baseline −4.0 ± 10.8 −13.4 ± 10.0†‡ −10.5 ± 11.9 −5.3 ± 12.0
(−8.9 to 0.8) (−17.6 to −9.3) (−16.0 to −4.9) (−10.5 to −0.2)
12 months 89.8 ± 22.3* 71.1 ± 19.8*†‡ 73.4 ± 17.1*†‡ 89.1 ± 22.6*
(80.8 to 100.3) (62.6 to 79.7) (64.5 to 82.2) (78.8 to 99.4)
Change from baseline −6.4 ± 15.9 −20.5 ± 13.3†‡ −19.6 ± 11.1†‡ −9.4 ± 16.3
(−13.3 to 0.4) (−26.2 to −14.7) (−25.3 to −13.9) (−16.8 to −1.9)
*p < 0.05, vs baseline; †p < 0.05, vs control; ‡p < 0.05, vs group C. CON control group; group A bone marrow mononuclear cell (BMC) infusion within 1 day after
percutaneous coronary intervention (PCI); group B BMC infusion at 3–7 days after PCI; group C BMC infusion at 7–30 days after PCI; LVEDV left ventricular
end-diastolic volume; LVESV left ventricular end-systolic volume
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hours after the primary PCI is as effective as BMC infu-
sion at 3 to 7 days after PCI. In the present study, BMC
infusion after 7 days (11.1 ± 3.3 days) had no significant
effects on the recovery of left ventricular function and
remolding as compared to the control group; this find-
ing was not consistent with the results reported by Fer-
nández-Aviles et al., who injected mononuclear stem
cells at an average of 2 weeks after infarction and re-
ported a comparable increase in left ventricular function
[21]. In another similar trial, patients with STEMI who
underwent successful primary PCI and administration of
intra-coronary BMCs at either 3 or 7 days following the
event showed recovery of global and regional left ven-
tricular function similar to that of placebo-treated pa-
tients [12]. The reasons for the different results are
unclear. The study by Fernández-Aviles et al. included
only a few patients and had no control group. The sam-
ple size in the TIME study was also small and the aver-
age LVEF of enrolled patients was >45 %. The TIME
study also suggested that, in STEMI patients, myocardial re-
pair was more dependent on baseline BMC characteristics(CD31+ BMC) than on whether the patient underwent
intracoronary BMC transplantation [22].
In most clinical trials, the average baseline LVEF of
AMI patients is approximately 50 % [23]. The subgroup
outcome from REPAIR-AMI indicated that patients with
an LVEF of <49 % received a greater benefit (7.5 % vs
5.5 %) from cell transplantation [24]. The magnitude of
left ventricular contractile recovery appears to be in-
versely related to the baseline LVEF. Patients enrolled in
our study had substantial functional impairment: on
average, the global LVEF at baseline was 41 %, which is
much lower than that reported by earlier studies. After
successful myocardial reperfusion and autologous BMC
transplantation, LVEF increased by 5–6 % at 6 months
and by 7–8 % at 12 months. These results are similar to
those of the subgroup with a lower baseline LVEF in
REPAIR-AMI. In addition, preliminary studies have sug-
gested that the number of cells transplanted plays a role
in the clinical outcome [4, 5, 25, 26]. In our study, the
marked beneficial effects of BMC infusion on the recov-
ery of contractile function were likely the result of the
larger number of cells delivered (6.9 ± 8.8 × 108); this
Huang et al. Stem Cell Research & Therapy  (2015) 6:112 Page 10 of 11number was almost ten times higher than the number of
cells delivered in BOOST or TOPCARE-AMI.
Compared to the control group, the incidence of indi-
vidual adverse clinical effects were lower in groups A
and B (p = 0.078 for the comparison with group A, and
p = 0.214 for the comparison with group B). These re-
sults suggest that BMC infusion reduces the risk of
chronic heart failure, which is a common complication
of myocardial infarction. Importantly, we have not found
that stem cell transplantation increases the rate of in-
stent restenosis and increases the hsCRP or cTnT levels.
Notably, there was no mortality at 12 months in any of
the groups. This is a moderate-risk population. The
average LVEF at baseline was 40.5 % to 46.3 %. The clin-
ical characteristics of these patients were lower CRP
peak levels and fewer three-vessel coronary artery le-
sions, which predicted better prognosis. Furthermore, al-
most all these patients took optimal medical treatments
including aspirin, statins, beta-blockers and angiotensin
converting enzyme inhibitors after PCI. Of course, the
small number of patients and the limited follow-up time
in this study might be related to the lower incidence of
adverse effects in this study. Thus, further work is still
needed on the safety of intracoronary BMC infusion des-
pite our previous results [27, 28].
There are a number of SPECT measurements to assess
myocardial perfusion defects, such as the two-day
201Tl-SPECT technique, 99mTc-MIBI-SPECT imaging
and exercise SPECT. In the present study, we used a
one-day 201Tl–SPECT technique because the baseline
SPECT data were obtained within a few days after myo-
cardial infarction. This was shown to be a safe and feas-
ible method in the present study.
Our study had several limitations. First, although the
control group received an intracoronary saline infusion
at the same time point as group A, we did not have con-
trol groups receiving the infusion at the same times
points as groups B and C (although saline infusion alone
has no effect on AMI [1–6]). Second, we did not label
the cells to estimate cell survival and homing rates, and
such observations might provide explanations for the
differences between our findings and those of other re-
searchers. In view of findings showing increased rates of
cell death associated with inflammation during the early
stage of infarction, the REPAIR-AMI trial suggested that
early cell infusions were less effective than those delayed
beyond 5 days. However, we found early infusion to be
as effective as infusion at 3–7 days. Our results might be
partly attributable to our delivery of a large number of
BMCs and the detection of a larger population of CD34-
positive cells in the BMCs of patients within 1 day after
AMI, compared to other studies. Additionally, we previ-
ously showed that myocardial stroma cell derived factor-1
(SDF-1) expression increased and peaked at the first daypost-AMI in rats; stroma cell derived factor-1 expression is
important for progenitor cell chemotaxis, homing, engraft-
ment, and retention in the damaged myocardium, and
BMC enrichment and angiogenesis in the host hearts were
more abundant in the infarcted heart. Third, cardiac mag-
netic resonance imaging is considered the best modality
to assess left ventricular remodeling and function after
myocardial infacrtion. Although we measured the in-
farcted area by cardiac magnetic resonance imaging at 6
and 12 months in some patients, the data were not in-
cluded in the present study because we did not perform
baseline magnetic resonance imaging at 2–3 days in all pa-
tients. Fourth, the benefits in functional parameters failed
to translate into clinically meaningful improvement in
outcomes, and the combined endpoint of death, myocar-
dial infarction, and rehospitalization for heart failure was
not significantly different at 1 year between the groups.
One explanation is that our sample size was too small. In
addition, only 85 patients completed the 6- and 12-month
follow-up periods. Owing to the small number of patients
and the duration of follow-up, our study was not powered
to assess the optimal timing. However, our results provide
insight into the optimal timing and sufficient background
for its assessment in a large-scale trial. Another possibility
is that the benefits of BMC infusion are associated with
the regeneration of the myocardium and vessels, and the
volume of tissue regeneration at 1 year may be too small to
compensate for the initial damage. Alternatively, the benefits
may be dependent on the presence of cytokines and growth
factors released from transplanted BMCs, which would have
disappeared at 1 year. Repeated BMC infusion at a certain
time after the initial therapy might improve the results [29].
Conclusion
In summary, the primary outcomes showed that, in AMI
patients, intracoronary BMC infusion within 24 hours
after the primary PCI is as effective as BMC infusion 3 to
7 days after primary PCI with respect to left ventricular
contractile function recovery and remodeling. Of course,
it needs further data from more trials.
Abbreviations
AMI: acute myocardial infarction; ANOVA: analysis of variance; BMC: bone
marrow mononuclear cell; CK: creatinine kinase; CON: control group;
cTnT: cardiac troponin T; hsCRP: high-sensitive C-reactive protein;
IRA: infarct-related artery; LVEDV: left ventricular end-diastolic volume;
LVEF: left ventricular ejection fraction; LVESV: left ventricular end-systolic
volume; PCI: percutaneous coronary intervention; SPECT: single photon
emission computed tomography; STEMI: ST-elevation myocardial infarction.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
RH and KY carried out BMC collection, isolation and preparation, and
participated in design and coordination and drafted the manuscript.
AS participated in design and performed the statistical analysis.
JQ and LG carried out primary PCI and repeated cardiac catheterization.
Huang et al. Stem Cell Research & Therapy  (2015) 6:112 Page 11 of 11YZ and YN carried out bone marrow puncture, BMC preparation and
coordination. KW participated in design and helped to draft the manuscript.
YZ performed the statistical analysis, participated in design and helped to
draft the manuscript. JG conceived the study, participated in design and
coordination and helped to draft the manuscript. All authors read and
approved the final manuscript.
Acknowledgments
The authors thank the nursing and technical staff of the catheterization
laboratory and nuclear medicine department (H Shi, S Cheng) of the
Zhongshan Hospital, Fudan University.
Funding sources
This work was supported by Liaoning Provincial natural Science Foundation
of China (2009A192), Shanghai Scientific Research Fund (03XD14010 and
06DJ14001), the National Natural Science Foundation of China (81100220),
National Keystone Basic Research Program (2006CB943704) and Ministry of
Science and Technology (2004BA714B05-2) (China).
Author details
1The First Affiliated Hospital of Dalian Medical University, 222 Zhongshan
Road, Dalian 116011, China. 2Shanghai Institute of Cardiovascular Diseases,
Zhongshan Hospital, Fudan University, 180 Feng Lin Road, Shanghai 200032,
China. 3Institutes of Biomedical Science, Fudan University, 138 Dong’an Road,
Shanghai 200032, China.
Received: 16 July 2014 Revised: 16 July 2014
Accepted: 20 May 2015
References
1. Angeli FS, Caramori PR, da Costa Escobar Piccoli J, Danzmann LC, Magedanz E,
Bertaso A, et al. Autologus transplantation of mononuclear bone marrow cells
after acute myocardial infarction: a PILOT study. Int J Cardiol. 2012;158:449–50.
2. Traverse JH, Henry TD, Pepine CJ, Willerson JT, Ellis SG. One-year follow-up
of intracoronary stem cell delivery on left ventricular function following
ST-elevation myocardial infarction. JAMA. 2014;311:301–2.
3. Delewi R, Hirsch A, Tijssen JG, Schächinger V, Wojakowski W, Roncalli J, et al.
Impact of intracoronary bone marrow cell therapy on left ventricular
function in the setting of ST-segment elevation myocardial infarction: a
collaborative meta-analysis. Eur Heart J. 2014;35:989–98.
4. Makkar RR, Smith RR, Cheng K, Malliaras K, Thomson LE, Berman D, et al.
Intracoronary cardiosphere-derived cells for heart regeneration after myocardial
infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet.
2012;379:895–904.
5. Schächinger V, Erbs S, Elsässer A, Haberbosch W, Hambrecht R, Hölschermann H,
et al. REPAIR-AMI Investigators. Improved clinical outcome after intracoronary
administration of bone-marrow-derived progenitor cells in acute myocardial
infarction: final 1-year results of the REPAIR-AMI trial. Eur Heart J. 2006;27:2775–83.
6. Wöhrle J, von Scheidt F, Schauwecker P, Wiesneth M, Markovic S,
Schrezenmeier H, et al. Impact of cell number and microvascular
obstruction in patients with bone-marrow derived cell therapy: final results
from the randomized, double-blind, placebo controlled intracoronary Stem
Cell therapy in patients with Acute Myocardial Infarction (SCAMI) trial. Clin
Res Cardiol. 2013;102:765–70.
7. Ge J, Li Y, Qian J, Shi J, Wang Q, Niu Y, et al. Efficacy of Emergent
Transcatheter Transplantation of Stem Cells for Treatment of Acute
Myocardial Infarction (TCT-STAMI). Heart. 2006;92:1764–7.
8. Gyöngyösi M, Lang I, Dettke M, Beran G, Graf S, Sochor H, et al. Combined
delivery approach of bone marrow mononuclear stem cells early and late
after myocardial infarction: the MYSTAR prospective, randomized study. Nat
Clin Pract Cardiovasc Med. 2009;6:70–81.
9. Sürder D, Schwitter J, Moccetti T, Astori G, Rufibach K, Plein S, et al. Cell-based
therapy for myocardial repair in patients with acute myocardial infarction:
rationale and study design of the SWiss multicenter Intracoronary Stem cells
Study in Acute Myocardial Infarction (SWISS-AMI). Am Heart J. 2010;160:58–64.
10. Otterstad JE. Measuring left ventricular volume and ejection fraction with
the biplane Simpson’s method. Heart. 2002;88:559–60.
11. Ho FM, Huang PJ, Liau CS, Lee FK, Chieng PU, Su CT, et al. Dobutamine
stress echocardiography compared with dipyridamole thallium-201
single-photon emission computed tomography in detecting coronary artery
disease. Eur Heart J. 1995;16:570–5.12. Traverse JH, Henry TD, Pepine CJ, Willerson JT, Zhao DX, Ellis SG, et al.
Cardiovascular Cell Therapy Research Network (CCTRN), effect of the use
and timing of bone marrow mononuclear cell delivery on left ventricular
function after acute myocardial infarction: the TIME randomized trial. JAMA.
2012;308:2380–9.
13. Plewka M, Krzemińska-Pakuła M, Lipiec P, Peruga JZ, Jezewski T, Kidawa M,
et al. Effect of intracoronary injection of mononuclear bone marrow stem
cells on left ventricular function in patients with acute myocardial infarction.
Am J Cardiol. 2009;104:1336–42.
14. Janssens S, Dubois C, Bogaert J, Theunissen K, Deroose C, Desmet M, et al.
Autologous bone marrow-derived stem-cell transfer in patients with
ST-segment elevation myocardial infarction: double-blind, randomized
controlled trial. Lancet. 2006;367:113–21.
15. Yao K, Huang R, Qian J, Cui J, Ge L, Li Y, et al. Administration of
intracoronary bone marrow mononuclear cells on chronic myocardial
infarction improves diastolic function. Heart. 2008;94:1147–53.
16. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in
myocardial infarction. Cardiovasc Res. 2002;53:31–47.
17. Saparov A, Chen CW, Beckman SA, Wang Y, Huard J. The role of
antioxidation and immunomodulation in postnatal multipotent stem
cell-mediated cardiac repair. Int J Mol Sci. 2013;14:16258–79.
18. Deten A, Volz HC, Briest W, Zimmer HG. Cardiac cytokine expression is
upregulated in the acute phase after myocardial infarction. Experimental
studies in rats. Cardiovasc Res. 2002;55:329–40.
19. Ma J, Ge J, Zhang S, Sun A, Shen J, Chen L, et al. Time course of myocardial
stromal cell-derived factor 1 expression and beneficial effects of intravenously
administered bone marrow stem cells in rats with experimental myocardial
infarction. Basic Res Cardial. 2005;100:217–23.
20. Zhang S, Sun A, Xu D, Yao K, Huang Z, Jin H, et al. Impact of timing on
efficacy and safety of intracoronary autologous bone marrow stem cells
transplantation in acute myocardial infarction: a pooled subgroup analysis
of randomized controlled trials. Clin Cardiol. 2009;32:458–66.
21. Fernández-Aviles F, San Román JA, García-Frade J, Fernández ME,
Peñarrubia MJ, de la Fuente L, et al. Experimental and clinical
regenerative capability of human bone marrow cells after myocardial
infarction. Circ Res. 2004;95:742–8.
22. Schutt RC, Trachtenberg B, Cooke JP, Traverse JH, Henry TD, Pepine CJ, et al. Bone
marrow characteristics associated with changes in infarct size after STEMI:
a biorepository evaluation from the CCTRN TIME Trial. Circ Res. 2015;116(1):99–107.
23. Traverse JH, Henry TD, Vaughan DE, Ellis SG, Pepine CJ, Willerson JT, et al.
Cardiovascular Cell Therapy Research Network. LateTIME: a phase-II, randomized,
double-blinded, placebo-controlled, pilot trial evaluating the safety and effect
of administration of bone marrow mononuclear cells 2 to 3 weeks after acute
myocardial infarction. Tex Heart Inst J. 2010;37:412–20.
24. Dill T, Schächinger V, Rolf A, Möllmann S, Thiele H, Tillmanns H, et al.
Intracoronary administration of bone marrow-derived progenitor cells
improves left ventricular function in patients at risk for adverse remodeling
after acute ST-segment elevation myocardial infarction: results of the
Reinfusion of Enriched Progenitor cells And Infarct Remodeling in Acute
Myocardial Infarction study (REPAIR-AMI) cardiac magnetic resonance
imaging substudy. Am Heart J. 2009;157:541–7.
25. Gao LR, Pei XT, Ding QA, Chen Y, Zhang NK, Chen HY, et al. A critical
challenge: dosage-related efficacy and acute complication intracoronary
injection of autologous bone marrow mesenchymal stem cell in acute
myocardial infarction. Int J Cardiol. 2013;168:3191–9.
26. Tambara K, Sakakibara Y, Sakaguchi G, Lu F, Premaratne GU, Lin X, et al.
Transplanted skeletal myoblasts can fully replace the infracted myocardium
when they survive in the host in large numbers. Circulation. 2003;108:259–63.
27. Yao K, Huang RC, Ge L, Qian JY, Li YL, Xu SK, et al. Observation on the
safety: clinical trial on intracoronary autologous bone marrow mononuclear
cells transplantation for acute myocardial infarction. Zhong Hua Xin Xue
Guan Bing Za Zhi (Chin). 2006;34:577–81.
28. Rongchong H. Stem cell therapy for the treatment of coronary heart disease:
safety evaluation. Zhong Hua Xin Xue Guan Bing Za Zhi (Chin). 2012;40:1–2.
29. Yao K, Huang R, Sun A, Qian J, Liu X, Ge L, et al. Repeated autologous bone
marrow mononuclear cell therapy in patients with large myocardial
infarction. Eur J Heart Fail. 2009;11:691–8.
